CompletedNot Applicable

Influence of Platform-switching on Bone Level Alterations: a 3 Year Randomized Clinical Trial (RCT).

25 participantsStarted 2007-02

Plain-language summary

The concept of platform-switching has been introduced to implant dentistry based on clinical observations of reduced periimplant crestal bone loss. However, published available data are controversial and most studies are limited to 12 months. The aim of the present RCT was to test the hypothesis that platform-switching has a positive impact on crestal bone level changes after 3 years.

Who can participate

Age range30 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * good general health * edentulous gap in the posterior mandible for placement of 2 implants * sufficient bone height above the alveolar nerve for placement of implants with a height of 9.5mm * bone width for placement of implants with diameter of 4mm * at least 4mm keratinized mucosa * medium or a thick soft tissue biotype Exclusion Criteria: * infectious disease * diabetes or osteopathy * active periodontitis * medication influencing bone metabolism * lactating or pregnant women

What they're measuring

Change of vertical implant bone level

Timeframe: Implant insertion (baseline), 3 months (reopening), 4 months (crown mounting), 12, 25 and 38 months

Trial details

NCT IDNCT01917305

SponsorSøren Jepsen

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2010-03

View on ClinicalTrials.gov More Periimplant Crestal Bone Level Changes trials